Elizabeth Jungman directs Pew’s work on public health, overseeing initiatives related to antibiotics and innovation and the safety of prescription drugs, over-the-counter medicines, and other consumer health care products.
Before joining Pew, she served as a senior health policy adviser with the U.S. Senate Committee on Health, Education, Labor, and Pensions, where she played a key role in drafting and negotiating the Food and Drug Administration Safety and Innovation Act of 2012, the FDA provisions in the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013, and the Drug Quality and Security Act of 2013, which included drug compounding and supply chain security measures.
Before moving to the Hill, Jungman was in private legal practice, counseling clients on a broad range of FDA regulatory matters and other health care issues related to the human pharmaceutical industry. She serves on FDA’s Pharmacy Compounding Advisory Committee. She has an undergraduate biology degree from Harvard College, a Juris Doctor from Georgetown University, and a master’s degree in public health from Johns Hopkins University.
Recent WorkView All
The Pew Charitable Trusts, together with the American Public Health Association, the Association for Accessible Medicines, the Biotechnology Innovation Organization, and the Pharmaceutical Research and Manufacturers of America, sent a letter to the acting secretary of the Department of Health and Human Services (HHS). Read More
Pew’s drug safety project has identified more than 50 reported compounding errors or potential errors associated with 1,197 adverse events, including 99 deaths, from 2001 to 2016. Because many such events may go unreported, this chart is likely an underestimation of the number of compounding errors since 2001. Contamination of sterile products was the most common error; others were the... Read More
The Pew Charitable Trusts, together with the American Public Health Association, the Association for Accessible Medicines, the Biotechnology Innovation Organization, the Pharmaceutical Research and Manufacturers of America, and Trust for America’s Health sent letters to the chairs and ranking members of the Appropriations Committees of the U.S. Senate and the U.S. House of... Read More